Patient P-01323

Synthetic patientNBL-101 · Day 110 · 55–64 · F · baseline S14Steering view · 3D Open companion preview

Therapy response

Stable

Tolerance

Deteriorating

GI state

Improving

Inflammatory state

Stable

Nutritional resilience

Improving

Discontinuation risk

54%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 NBL-101 started — Baseline state S14
Day 31 NP-02 recommended — Dietary Support Protocol NP-02
Day 32 Patient accepted — Started NP-02 in the companion
Day 42 GI symptom burden −12% vs expected — Dietary Support Protocol NP-02
Day 46 SC-12 recommended — Supportive Compound SC-12
Day 47 Patient accepted — Started SC-12 in the companion
Day 48 Tolerance state changed — Unstable → Improving
Day 52 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 53 GI symptom burden −14% vs expected — Supportive Compound SC-12
Day 59 Tolerance state changed — Unstable → Improving
Day 60 GI-04 recommended — GI Support Protocol GI-04
Day 61 Patient accepted — Started GI-04 in the companion
Day 69 GI symptom burden −27% vs expected — GI Support Protocol GI-04
Day 75 Tolerance state changed — Unstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 52.

Primary contributors, last 14 days

GI instability-9
Toxicity+7
Nutritional resilience+4

What helped?

Dietary Support Protocol NP-02Day 31
Result: symptom burden −12%
Supportive Compound SC-12Day 46
Result: symptom burden −14%
GI Support Protocol GI-04Day 60
Result: symptom burden −27%

LIFE OS recommendation

Monitoring Escalation ME-01

72%

probability of meaningful tolerance improvement

284 similar trajectories
100% showed improvement
median effect visible after 3 days

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

GI burden

Companion

36.3/100

stable · +1.7 vs previous 14 d

Toxicity

Blood

43.2/100

improving · -4.4 vs previous 14 d

Sleep quality

Wearable

29.8/100

worsening · -1.4 vs previous 14 d

Energy level

Daily log

4/10

stable · -0.1 vs previous 14 d

Stress level

Daily log

6.5/10

stable · +0.1 vs previous 14 d

Steps

Wearable

6,783

worsening · -398 vs previous 14 d

Adherence

Companion

58.6 %

stable · +1.3 vs previous 14 d

This trajectory is decaying — what would help, what would not

Steering view →

Heading towards restoration · 49 from the failing basin, 38 from restoration.

Would help

ME-01 Monitoring Escalation
100% improved among 75 similar · onset 3 d · confidence 60%
CR-01 Clinician Review
100% improved among 8 similar · onset 5 d · confidence 60%

Would not help

Keep histamine low
GI +5.4 next day on high-intake days · n 22
Keep fat low
GI +3.1 next day on high-intake days · n 17

State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

Histamine load
+5.4detractor · 95%
Dietary fat load
+3.1detractor · 85%
Simple carbohydrates
+2.2no signal · 50%
Insoluble fibre
+2.2no signal · 51%
Spicy / capsaicin
+1.5no signal · 29%
Alcohol
+1.2no signal · 25%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Inflammatory signalling ↓65
- DNAIL6 -174 variant raises baseline inflammatory tone
- BloodInflammatory load index 41
- WearableHRV 27 ms, trending down
Mucosal barrier integrity ↓60
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
Autonomic recovery ↓45
- WearableResting HR 83 bpm
- WearableShort sleep window
Butyrate / short-chain fatty acid production ↓25
- MicrobiomeF. prausnitzii depleted
Drug metabolism and exposure ↑20
- BloodToxicity index 43

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
IL6 -174 G/C
Higher inflammatory tone
CYP2D6 Normal metabolizer
Expected exposure

Microbiome

Shannon diversity 3 · butyrate capacity 47/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiLow
Bacteroides fragilisNormal
Bifidobacterium longumLow
EnterobacteriaceaeNormal

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 26 ms
Sleep: 6.5 h
Steps: 7,641
Resting HR: 80 bpm

Daily log: GI score 36, nutritional resilience 51, adherence 59.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Keep meals regular; three to four moderate portions spaced through the day
Include a cooked vegetable portion with each main meal
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Avoid known triggers for now: fried or oily food, dairy, alcohol

What to do

Log the daily check-in; one line is enough
Keep the current walking rhythm
Protect a 7.5-hour sleep window; screens off 30 minutes before
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the scheduled dose as agreed with your care team
No additional supplements this week
Fictional demo item: continue vitamin D as before

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-01327	45%	S01	GI-04	improved	56
P-01688	45%	S01	GI-04	improved	40
P-01310	32%	S01	—	—	57
P-01813	31%	S01	NP-02	no change	40
P-01821	27%	S01	—	—	58
P-01604	26%	S01	—	—	71
P-01823	26%	S01	—	—	57
P-01877	26%	S01	CR-01	improved	67
P-01635	47%	S02	GI-04	improved	49
P-01452	33%	S02	GI-04	improved	46
P-01459	30%	S02	—	—	51
P-01499	27%	S02	—	—	65